CyDex Pharmaceuticals cydexpharma.com


Public lists: Pharma Startups (4732)

CyDex Pharmaceuticals develops drugs specifically designed to address limitations of current therapies for conditions such as bipolar disorder, schizophrenia, fungus, and canine motion sickness.

CyDex Pharmaceuticals develops drugs specifically designed to address limitations of current therapies for conditions such as bipolar disorder, schizophrenia, fungus, and canine motion sickness.

Company (Acquired)

Phone: 913-685-8850

Fax:

10513 West 84th Terrace

Lenexa, 66214
Kansas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
CyDex Pharmaceuticals $29M Jan 24, 2011
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related CyDex Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 9 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Syndax Pharmaceuticals

Waltham, Massachusetts, United States
IPO / Went publicSyndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer. Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated in a Ph...Show allLogin to see details

Celera Genomics

Rockville, Maryland, United States
AcquiredCelera Genomics is one of three business segments of Applera Corporation. Celera Genomic's mission is to discover and develop meaningful new therapies that improve human health. We are applying our diverse genomics, bioinformatics, proteomics, medicinal chemistry and biology technology platforms to identify and validate drug targets, and to discover novel therapeutics. Celera Genomics currently has a portfolio of programs based primarily on protease inhibitors for three major therapeutic areas: ...Show allLogin to see details
See all 15 competitors